| Date Filed | Type | Description |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/11/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/06/2023 |
SC 13G/A
| BIGGER CAPITAL FUND L P reports a 6.6% stake in Actinium Pharmaceuticals, Inc. |
| 12/30/2022 |
8-K
| Quarterly results |
| 12/09/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 12/09/2022 |
8-K
| Quarterly results |
| 11/21/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/31/2022 |
8-K
| Quarterly results |
| 08/19/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/19/2022 |
4
| SETH SANDESH (CEO) has filed a Form 4 on Actinium Pharmaceuticals, Inc.|
Txns:
| Granted 300,000 shares
@ $0 |
|
| 08/12/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/01/2022 |
4
| O'Loughlin Steve (CFO) has filed a Form 4 on Actinium Pharmaceuticals, Inc.|
Txns:
| Granted 256,438 options to buy
@ $0 |
|
| 07/01/2022 |
4
| Nicholson, C. David (Director) has filed a Form 4 on Actinium Pharmaceuticals, Inc.|
Txns:
| Granted 72,156 options to buy
@ $0 |
|
| 07/01/2022 |
4
| Steinhart Richard I (Director) has filed a Form 4 on Actinium Pharmaceuticals, Inc.|
Txns:
| Granted 72,156 options to buy
@ $0 |
|
| 07/01/2022 |
4
| Shetty Ajit (Director) has filed a Form 4 on Actinium Pharmaceuticals, Inc.|
Txns:
| Granted 72,156 options to buy
@ $0 |
|
| 07/01/2022 |
4
| SETH SANDESH (CEO) has filed a Form 4 on Actinium Pharmaceuticals, Inc.|
Txns:
| Granted 827,366 options to buy
@ $0 |
|
| 07/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/29/2022 |
8-K
| Quarterly results |
| 06/28/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/13/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 04/13/2022 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 03/25/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 02/08/2022 |
SC 13G/A
| BIGGER CAPITAL FUND L P reports a 6% stake in Actinium Pharmaceuticals, Inc. |
| 11/12/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 11/09/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/18/2021 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 09/23/2021 |
8-K
| Quarterly results |
| 09/03/2021 |
4
| Chell Jeffrey W. (Director) has filed a Form 4 on Actinium Pharmaceuticals, Inc.|
Txns:
| Granted 18,351 options to buy
@ $0 |
|
| 09/03/2021 |
4
| Berger Mark Stanley (Chief Medical Officer) has filed a Form 4 on Actinium Pharmaceuticals, Inc.|
Txns:
| Granted 67,164 options to buy
@ $0 |
|
| 09/03/2021 |
4
| Shetty Ajit (Director) has filed a Form 4 on Actinium Pharmaceuticals, Inc.|
Txns:
| Granted 18,351 options to buy
@ $0 |
|
|